Boston, MANCT05952583Now EnrollingIRB Ready

Twin; Pregnancy, Affecting Fetus or Newborn Clinical Trial in Boston, MA

Access cutting-edge twin; pregnancy, affecting fetus or newborn treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Leiden University Medical Center

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access twin; pregnancy, affecting fetus or newborn specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related twin; pregnancy, affecting fetus or newborn treatment provided free

Apply for This Boston Location

Check if you qualify for this twin; pregnancy, affecting fetus or newborn clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Twin; Pregnancy, Affecting Fetus or Newborn Study in Boston

Optimal diagnostic management and underlying pathophysiological mechanisms of selective fetal growth restriction (sFGR) in monochorionic diamniotic (MCDA) twin pregnancies have not been fully clarified. The current diagnostic classification system based on three different umbilical artery flow patterns has no increasing scale of severity and the predictive value is limited. Since there is no treatment available for sFGR, predicting fetal deterioration is key in preventing single or double fetal demise. Outcome prediction is furthermore important in the selection of cases that will be offered selective reduction (to provide the larger twin with better prospects), as well as determining monitor frequency and possible hospital admission. As outcome prediction is clinically challenging, patient counselling is too, and parents often encounter a great deal of uncertainty during the pregnancy. Furthermore, little is known about the brain development of sFGR children (both during pregnancy and after birth). Moreover, the psychological impact of an sFGR pregnancy of the future parent)s) has not been studied before. The impact of these factors should be taken into account during patient counseling, which is currently not the case. By our knowledge, this is the first international, multicenter, prospective cohort study on that will address the abovementioned questions and knowledge gaps in MCDA pregnancies complicated by selective fetal growth restriction.

Sponsor: Leiden University Medical Center

Who Can Participate

Inclusion Criteria

MCDA twin pregnancy
Diagnosis of sFGR before 28+0 weeks of GA (independent of Doppler flows)
Pregnant woman ≥ 18 years and able to consent
Partner (who has (future) parental responsibility - if applicable) ≥ 18 years and able to consent
Written informed consent of both parents (if applicable) for participation in the longitudinal follow-up until 2 years after birth)

Exclusion Criteria

The presence of lethal anomalies (one or both fetuses)
Multiple pregnancy higher order than twins;
TTTS/TAPS present at moment of sFGR diagnosis.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT05952583) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Twin; Pregnancy, Affecting Fetus or Newborn Treatment Options in Boston, MA

If you're searching for twin; pregnancy, affecting fetus or newborn treatment options in Boston, MA, this clinical trial (NCT05952583) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced twin; pregnancy, affecting fetus or newborn specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all twin; pregnancy, affecting fetus or newborn clinical trials near you to find additional studies recruiting in your area.

More Atrial Fibrillation Trials in Boston, MA

See all atrial fibrillation clinical trials recruiting in Boston — not just this study.

Browse Atrial Fibrillation Trials in Boston

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA